ME-401-003 (TIDAL): A multicenter, randomized, double-blind, placebo-controlled, two-arm, phase 2 study of ME-401 investigating continuous and intermittent dosing schedules in patients with relapsed/refractory follicular lymphoma Meeting Abstract
| Authors: | Zelenetz, A. D.; Zinzani, P. L. L.; Chan, H.; Buske, C.; Ribrag, V.; Cunningham, D.; Jurczak, W.; Abrisqueta, P.; Li, J.; Gorbatchevsky, I.; Brown, J. R. |
| Abstract Title: | ME-401-003 (TIDAL): A multicenter, randomized, double-blind, placebo-controlled, two-arm, phase 2 study of ME-401 investigating continuous and intermittent dosing schedules in patients with relapsed/refractory follicular lymphoma |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164605317 |
| DOI: | 10.1182/blood-2019-124326 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 5244 -- Source: Wos |
